Machine-learning analysis of plasma metabolomic fingerprints yields a 21-metabolite gastric-cancer panel validated across multicentre cohorts
In a multicentre study, machine-learning analysis of plasma metabolic fingerprints from 1,944 retrospective participants selected a 21-metabolite panel that differentiated gastric-cancer from non-cancer cohorts; five model types achieved AUCs of 0.921–0.971 in discovery and 0.907–0.940 in external verification. Prospective testing in 264 participants using both NPELDI-MS and UPLC-MS reported diagnostic AUCs of 0.855–0.918 and 0.856–0.916, respectively. The paper also reports a four-metabolite prognostic score based on retrospective survival data.
Technology: Neural network, lasso regression, ridge regression, support-vector machine and random-forest models applied to plasma metabolic fingerprints
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: prospective or independent check
- Tested: In a multicentre study, machine-learning analysis of plasma metabolic fingerprints from 1,944 retrospective participants selected a 21-metabolite panel that differentiated gastric-cancer from non-cancer cohorts; five model types achieved AUCs of 0.921–0.971 in discovery and 0.907–0.940 in external verification.
- Still unknown: The panel was evaluated in selected clinical cohorts and is not established for routine screening or clinical use. Prospective validation was at one lead center, and only six panel metabolites were robustly detected by confirmatory UPLC-MS under the reported testing. Model performance does not show that the panel is causal or improves outcomes. Primary full text/abstract checked; no independent replication assessed.
- AI role: The study used machine-learning feature selection/modeling (including logistic-regression coefficient filtering) to identify and evaluate a 21-metabolite diagnostic panel from high-throughput mass-spectrometry fingerprints; classifiers were then validated on independent retrospective and prospective cohorts.
Evidence sources: https://gut.bmj.com/content/72/11/2051
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 95 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.